Following a national search, Roswell Park Comprehensive Cancer Center has promoted Pawel Kalinski, MD, PhD, to Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology, and Senior Vice President for Team Science.
On staff at Roswell Park since 2017, Dr. Kalinski has helped to elevate both the profile and potential of Roswell Park’s immuno-oncology team. He previously served as Vice Chair for Translational Research, Director of Cancer Vaccine and Dendritic Cell Therapies, Rustum Family Endowed Professor for Molecular Therapeutics and Translational Research, and Co-Leader of the Tumor Immunology & Immunotherapy Program.
Pawel Kalinski, MD, PhD
Candace S. Johnson, PhD
“The work Dr. Kalinski leads is stunning in its scope, its uniqueness, and its potential for improving patient care and survival,” said Candace S. Johnson, PhD, President and Chief Executive Officer and M&T Bank Presidential Chair in Leadership at Roswell Park. “We look forward to seeing all that he will accomplish and the achievements he will inspire our team to realize.”
Dr. Kalinski directs a portfolio of more than $22.5 million in active grants. They include a $14.5 million award from the National Cancer Institute for a multicenter collaboration supporting five separate collaborative clinical trials and a $6.42 million project that’s part of a larger U.S. Department of Defense Breakthrough Award, led by Dr. Kalinski himself, which supports two clinical trials.
Dr. Kalinski’s role in leading team-science initiatives at Roswell Park will be particularly important, since it represents an opportunity to promote interactions between laboratory and clinical faculty in advancing outstanding science and developing effective partnerships with those in academia and the biotech and pharma sectors.
Dr. Kalinski is a graduate of Warsaw Medical Academy in Poland and the University of Amsterdam in the Netherlands. He is active in the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society of Clinical Investigation.
